Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161246 · ClinicalTrials.gov registry record · Phase 4
A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction
A Phase 4 study of Injection Site Discomfort, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06161246 is a Phase 4 study of Injection Site Discomfort that has completed, run by Galderma R&D. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06161246, a Phase 4 study of Injection Site Discomfort, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single-center, randomized, split-face, controlled study to assess the effect of comfort intervention on pain during treatment injection compared against non-comfort intervention.
Conditions Studied
Interventions
- DEVICE Vibrating Beauty Bar
Study Locations (1)
Illinois
- DeNova Research - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-10-23 |
| Est. Completion | 2024-02-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06161246
The ClinicalTrials.gov registry entry for NCT06161246 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Injection Site Discomfort appearing as the primary indexed condition, and to 1 intervention - of which Vibrating Beauty Bar is the first listed.
NCT06161246 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06161246 about?
NCT06161246 is a clinical study titled "A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction". This is an open-label, single-center, randomized, split-face, controlled study to assess the effect of comfort intervention on pain during treatment injection compared against non-comfort intervention.
What is the current status of trial NCT06161246?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2023-10-23. Estimated completion is 2024-02-15.
What conditions does trial NCT06161246 study?
This clinical trial studies the following conditions: Injection Site Discomfort.
What interventions are being tested in trial NCT06161246?
The interventions under investigation include: Vibrating Beauty Bar (DEVICE).
Who is sponsoring clinical trial NCT06161246?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06161246 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.